ARCT

#3503
Arcturus Therapeutics Holdings Inc. Common Stock
8.63 USD
+2.01%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
8.62
8.69
Rango anual
5.86
24.14
Cambio diario
+2.01%
Variación mensual
+27.10%
Variación en los últimos 6 meses
-59.46%
Cambio anual
-16.21%
Cierres anteriores
8.46
Abrir
8.68
Bid
Ask
Mínimo
8.62
High
8.69
Volumen
56
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Noticias